Alzamend Neuro (ALZN) Competitors $3.54 +0.03 (+0.71%) As of 01:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALZN vs. HOTH, LSB, BCDA, BLRX, DWTX, PHXM, ATHA, TLPH, CYCN, and APREShould you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include Hoth Therapeutics (HOTH), Lakeshore Biopharma (LSB), BioCardia (BCDA), BioLineRx (BLRX), Dogwood Therapeutics (DWTX), PHAXIAM Therapeutics (PHXM), Athira Pharma (ATHA), Talphera (TLPH), Cyclerion Therapeutics (CYCN), and Aprea Therapeutics (APRE). These companies are all part of the "pharmaceutical products" industry. Alzamend Neuro vs. Hoth Therapeutics Lakeshore Biopharma BioCardia BioLineRx Dogwood Therapeutics PHAXIAM Therapeutics Athira Pharma Talphera Cyclerion Therapeutics Aprea Therapeutics Alzamend Neuro (NASDAQ:ALZN) and Hoth Therapeutics (NASDAQ:HOTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment. Does the media prefer ALZN or HOTH? In the previous week, Alzamend Neuro had 3 more articles in the media than Hoth Therapeutics. MarketBeat recorded 3 mentions for Alzamend Neuro and 0 mentions for Hoth Therapeutics. Hoth Therapeutics' average media sentiment score of 0.98 beat Alzamend Neuro's score of 0.00 indicating that Hoth Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Alzamend Neuro Neutral Hoth Therapeutics Positive Does the MarketBeat Community prefer ALZN or HOTH? Hoth Therapeutics received 71 more outperform votes than Alzamend Neuro when rated by MarketBeat users. However, 100.00% of users gave Alzamend Neuro an outperform vote while only 67.24% of users gave Hoth Therapeutics an outperform vote. CompanyUnderperformOutperformAlzamend NeuroOutperform Votes7100.00% Underperform VotesNo VotesHoth TherapeuticsOutperform Votes7867.24% Underperform Votes3832.76% Which has more volatility and risk, ALZN or HOTH? Alzamend Neuro has a beta of -0.16, indicating that its stock price is 116% less volatile than the S&P 500. Comparatively, Hoth Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Do analysts rate ALZN or HOTH? Alzamend Neuro presently has a consensus target price of $180.00, indicating a potential upside of 5,013.64%. Hoth Therapeutics has a consensus target price of $4.00, indicating a potential upside of 379.04%. Given Alzamend Neuro's higher possible upside, equities analysts plainly believe Alzamend Neuro is more favorable than Hoth Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do institutionals & insiders have more ownership in ALZN or HOTH? 49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 7.1% of Hoth Therapeutics shares are held by institutional investors. 30.2% of Alzamend Neuro shares are held by company insiders. Comparatively, 10.6% of Hoth Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has stronger valuation and earnings, ALZN or HOTH? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlzamend NeuroN/AN/A-$9.95MN/AN/AHoth TherapeuticsN/AN/A-$7.84M-$1.14-0.73 Is ALZN or HOTH more profitable? Alzamend Neuro's return on equity of 0.00% beat Hoth Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alzamend NeuroN/A N/A -289.14% Hoth Therapeutics N/A -89.68%-82.61% SummaryHoth Therapeutics beats Alzamend Neuro on 8 of the 14 factors compared between the two stocks. Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALZN vs. The Competition Export to ExcelMetricAlzamend NeuroPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.82M$6.53B$5.38B$8.39BDividend YieldN/A2.65%5.21%4.10%P/E RatioN/A8.9226.8019.71Price / SalesN/A252.24389.55117.28Price / CashN/A65.8538.2534.62Price / Book-1.006.466.804.50Net Income-$9.95M$143.98M$3.23B$248.18M7 Day Performance6.99%2.03%1.53%0.23%1 Month Performance-43.32%4.11%10.05%12.39%1 Year Performance-93.69%-2.87%16.75%7.07% Alzamend Neuro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALZNAlzamend Neuro2.9949 of 5 stars$3.55+0.7%$180.00+4,977.6%-93.9%$2.84MN/A0.004HOTHHoth Therapeutics3.2945 of 5 stars$0.84-1.1%$4.00+375.6%-29.5%$11.10MN/A-0.644Analyst DowngradeGap DownLSBLakeshore Biopharma0.7068 of 5 stars$1.19+5.2%N/AN/A$11.07M$672.27M0.00773Positive NewsGap UpBCDABioCardia2.5624 of 5 stars$2.13-3.2%$25.00+1,073.7%-69.1%$11.03M$58,000.00-0.5140BLRXBioLineRx1.6475 of 5 stars$3.30+0.8%$26.00+689.1%-85.4%$10.97M$28.94M-0.3740Upcoming EarningsDWTXDogwood Therapeutics1.1913 of 5 stars$5.60-1.9%$10.00+78.6%N/A$10.75MN/A-0.865Gap DownPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049ATHAAthira Pharma1.7032 of 5 stars$0.27-0.7%$13.83+5,023.5%-89.4%$10.54MN/A-0.0940TLPHTalphera2.8182 of 5 stars$0.51-0.6%$5.00+886.2%-51.8%$10.40M$281,000.00-0.7319Gap DownCYCNCyclerion Therapeutics0.8264 of 5 stars$3.10-0.3%N/A+18.1%$9.95M$2.08M-2.6730Positive NewsAPREAprea Therapeutics3.0671 of 5 stars$1.79-3.0%$15.50+768.3%-68.6%$9.87M$580,000.00-0.647Analyst RevisionGap Down Related Companies and Tools Related Companies Hoth Therapeutics Competitors Lakeshore Biopharma Competitors BioCardia Competitors BioLineRx Competitors Dogwood Therapeutics Competitors PHAXIAM Therapeutics Competitors Athira Pharma Competitors Talphera Competitors Cyclerion Therapeutics Competitors Aprea Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALZN) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Bloodbath Coming on June 1st?If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALZN Stock Free ALZN Stock Alerts